At a glance
This program funds drug development for Alzheimer’s disease, including work on small molecules, natural products, and biologics, from early optimization through IND-enabling studies and initial Phase I clinical testing. Eligible applicants are researchers with projects that fit the program’s early or late stage entry criteria; the notice does not state award size or number of awards in the text provided. No cost-share requirement is stated. The program is limited to drug development for Alzheimer’s disease and excludes basic research, stand-alone efficacy studies, stand-alone clinical trials, studies beyond Phase I, anti-amyloid and anti-tau immunotherapies, generic or off-patent compounds, repurposing or new formulations of previously approved compounds, combination therapies, and biomarker or diagnostic projects.
What it funds
Official description from grants.gov
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.
Who can apply
- City or township governments
- County governments
- For-profit organizations other than small businesses
- Independent school districts
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Others
- Private institutions of higher education
- Public and State controlled institutions of higher education
- Public housing authorities / Indian housing authorities
- Small businesses
- Special district governments
- State governments